Vanda also sells sleep disorder drug Hetlioz, which reached the market in 2014, and relapsing multiple sclerosis treatment ...

A groundbreaking oral treatment for thalassemia, Mitapivat, has received US FDA approval, offering hope for adults with this ...

DelveInsight’s Thalassemia Market Insightsreport includes a comprehensive understanding of current treatment practices, emerging thalassemia drugs, market share of individual therapies, and current ...

The US FDA has approved mitapivat, the first oral medicine for treating anemia caused by thalassemia. At present, mitapivat ...

Wilmington, Delaware, United States, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global thalassemia treatment market is slated to be valued at US$ 1.5 billion in 2031, ...

The US Food and Drug Administrations (FDA) approval of the first-ever oral pill for anaemia in adults with thalassemia marks ...

AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or ...

Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "Thalassemia Market by Treatment Type, by Type, by Distribution Channel, and by Region" report has been added to ResearchAndMarkets.com's offering. The ...

The treatment for thalassemia can vary greatly according to the individual circumstances and the presenting symptoms. Some patients may carry a gene mutation but not experience any symptoms, also ...

While the inconsistencies in the demand and supply of blood impacts many people across the country, one of the most vulnerable group are the thalassemic patients. Thalassemia comes from the Greek word ...